Prognostic Value of eGFR and NT-proBNP in Patients with Chronic Heart Failure Complicated with Atrial Fibrillation
-
摘要:
目的 探讨eGFR和血清NT-proBNP对慢性心力衰竭合并房颤患者预后的预测价值。 方法 选取2018年1月至2019年12月期间住院的慢性心力衰竭合并房颤患者139例。测定患者的血清肌酐及NT-proBNP，根据肾脏病膳食改良预测方程计算患者的估测肾小球滤过率（eGFR）。随访入选患者出院后的全因死亡情况。应用Logistic回归分析慢性心力衰竭合并房颤患者随访期间发生全因死亡的危险因素。采用ROC曲线分析eGFR和血清NT-proBNP在慢性心力衰竭合并房颤患者预后中的价值。生存分析使用Kaplan-Meier法，检验用Log-rank法。 结果 随访期间有65例患者死亡，发生率为46.76%。eGFR预测慢性心力衰竭合并房颤患者不发生全因死亡的曲线下面积为0.651（95%CI：0.562～0.740），敏感度为57.70%，特异度为69.20%。血清NT-proBNP预测慢性心力衰竭合并房颤患者发生全因死亡的曲线下面积为0.720（95%CI：0.638～0.803），敏感度为69.20%，特异度为67.30%。eGFR低水平组患者随访期间累积生存率明显低于eGFR高水平组，Log-rank的检验统计值为9.21，P = 0.002。NT-proBNP高水平组患者随访期间累积生存率明显低于NT-proBNP低水平组，Log-rank的检验统计值为16.91，P < 0.001。 结论 eGFR和血清NT-proBNP对慢性心力衰竭合并房颤患者的近期预后有一定预测价值。 Abstract:Objective To investigate the prognostic value of eGFR and serum NT-proBNP in patients with chronic heart failure complicated with atrial fibrillation. Methods From January 2018 to December 2019, 139 hospitalized patients with chronic heart failure complicated with atrial fibrillation were selected. The serum creatinine and NT-proBNP of the patients were measured, and the estimated glomerular filtration rate （eGFR） of the patients was calculated according to theequationofModification of Diet in Renal Disease. All-cause deaths after discharge were followed up. Logistic regression was used to analyze the risk factors of all-cause death in chronic heart failure complicated with atrial fibrillation during the follow-up period. ROC curve was used to analyze the prognostic value of eGFR and serum NT-proBNP in patients with chronic heart failure complicated with atrial fibrillation.Kaplan-meier method was used to draw the survival curve, and log-rank test was used for survival analysis. Results During the follow-up, 65 patients were found dead. The incidence was 46.76%. The area under the curve of eGFR-in predicting the absence of all-cause death in patients with chronic heart failure and atrial fibrillation was 0.651 （95%CI: 0.562 ～ 0.740）.The sensitivity was 57.70%, and the specificity was 69.20%. The area under the curve of serum NT-proBNP for predicting all-cause death in patients with chronic heart failure complicated with atrial fibrillation was 0.720 （95%CI: 0.638 ～ 0.803）.The sensitivity was 69.20%, and the specificity was 67.30%. The cumulative survival rate of patients in the low-eGFR group was significantly lower than that in the high-eGFR group during follow-up. The Log-rank value was 9.21, P = 0.002. During the follow-up, the cumulative survival rate of patients in the high level of NT-proBNP group was significantly lower than that in the low level of NT-proBNP group. The statistical value of Log-rank test was 16.91, P < 0.001. Conclusion eGFR and serum NT-proBNP have certain predictive value for the short-term prognosis of patients with chronic heart failure complicated with atrial fibrillation. -
图 1 eGFR预测CHF合并Af患者不发生全因死亡的ROC曲线
Figure 1. ROC curve of eGFR in predicting the absence of all-cause death in patients with CHF complicated with Af
图 2 血清NT-proBNP预测CHF合并Af患者发生全因死亡的ROC曲线
Figure 2. Serum NT-proBNP predicted the ROC curve of all-cause death in patients with CHF complicated with Af
图 3 不同eGFR分组的CHF合并Af患者随访期间累积生存率情况的比较
Figure 3. Comparison of follow-up cumulative survival rate in patients with CHF combined with Af in different eGFR groups
图 4 不同NT-proBNP分组的CHF合并Af患者随访期间累积生存率情况的比较
Figure 4. Comparison of follow-up cumulative survival rate in patients with CHF combined with Af in different NT-proBNP groups
表 1 入选患者的基本特征[
$ \bar x \pm s $ /n（%）]Table 1. Basic characteristics of the selected patients [
$ \bar x \pm s$ /n（%）]基本特征 具体值 年龄（岁） 73.68 ± 9.21 男性 57（41.01） 心功能分级 心功能II级 4（2.88） 心功能III级 27（19.42） 心功能IV级 108（77.70） 基础心脏病 冠心病 97（69.78） 心脏瓣膜病 20 （14.39） 心肌病 12 （8.63） 高血压性心脏病 5（3.60） 其他 5（3.60） 血清肌酐（μmol/L） 96.47 ± 38.39 Lg（NT-proBNP） 3.55 ± 0.47 eGFR[mL/（min·1.73m2）] 84.55 ± 31.63 左室射血分数 0.49 ± 0.13 注：Lg（NT-proBNP）为NT-proBNP的对数值。 
下载: 导出CSV
表 2 Logistic回归分析入选患者随访期间发生全因死亡的危险因素
Table 2. Logistic regression analysis risk factors for all-cause death in selected patients during follow-up
变量 B SE Wald P OR 95%CI 年龄 0.040 0.270 2.231 0.135 1.041 0.988～1.096 性别 −0.599 0.573 1.095 0.295 0.549 0.179～1.688 心功能分级 −0.026 0.485 0.003 0.958 0.975 0.376～2.524 血清肌酐 0.000 0.013 0.002 0.968 0.999 0.974～1.025 NT-proBNP 0.000 0.000 6.295 0.012 1.000 1.000～1.000 eGFR 0.070 0.029 6.017 0.014 1.073 1.014～1.135 左室射血分数 −0.014 0.017 0.708 0.400 0.986 0.954～1.019
下载: 导出CSV
-
[1] Carlisle M A,Fudim M,DeVore A D,et al. Heart failure and atrial fibrillation,like fire and fury[J]. JACC Heart Fail,2019,7(6):447-456. doi: 10.1016/j.jchf.2019.03.005 [2] 徐永玄,杨萍,郭涛. 房颤发生机制及治疗新进展[J]. 昆明医科大学学报,2019,40(5):135-138. doi: 10.3969/j.issn.1003-4706.2019.05.026 [3] 莘琳琳,李禹龙,袁慧. 心力衰竭相关标志物研究进展[J]. 医学研究杂志,2021,50(2):5-8. [4] 李俊贤,林娅,赵新艳,等. 血浆NT-proBNP水平在慢性心衰中的诊断及预后评估[J]. 中国实用医药,2020,15(22):8-10. [5] 湛勇,王爽. 血清胱抑素C及NT-proBNP 与慢性心力衰竭患者疾病严重程度及预后相关性研究[J]. 医学理论与实践,2020,33(2):173-175. [6] 李雨濛,胡元会,商秀洋,等. 不同肾功能评价指标对慢性心力衰竭患者远期预后的预测价值[J]. 中国循证心血管医学杂志,2020,12(7):816-819. doi: 10.3969/j.issn.1674-4055.2020.07.10 [7] Raman M,Middleton R J,Kalra P A,et al. Estimating renal function in old people:an in-depth review[J]. Int Urol Nephrol,2017,49(11):1979-1988. doi: 10.1007/s11255-017-1682-z [8] 全国eGFR课题协作组. MDRD方程在我国慢性肾脏病患者中的改良和评估[J]. 中华肾脏病杂志,2006,22(10):589-595. doi: 10.3760/j.issn:1001-7097.2006.10.002 [9] 赵金芳,田艳珍. 老年慢性心力衰竭患者氨基末端脑利钠肽前体、甲状腺激素水平变化及其对病情、预后的影响[J]. 临床误诊误治,2020,33(9):54-58. doi: 10.3969/j.issn.1002-3429.2020.09.013 [10] 郭洪森. 老年人慢性心力衰竭并发肾功能不全临床特征及预后研究[J]. 中外医疗,2021,40(6):26-28. [11] 安英男,唐敏,赵丽君. 血清胱抑素C和N末端脑钠肽前体与慢性心力衰竭患者疾病严重程度及预后的相关性分析[J]. 解放军医药杂志,2019,31(5):71-74. doi: 10.3969/j.issn.2095-140X.2019.05.017 [12] Hunt S A,Abraham W T,Chin M H,et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure):developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation:endorsed by the Heart Rhythm Society[J]. Circulation,2005,112(12):e154-235. [13] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志,2014,42(2):98-122. [14] Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J,2016,37(38):2893-2962. doi: 10.1093/eurheartj/ehw210 [15] Sartipy U,Dahlström U,Fu M,et al. Atrial fibrillation in heart failure with preserved,mid-range,and reduced ejection fraction[J]. JACC Heart Fail,2017,5(8):565-574. doi: 10.1016/j.jchf.2017.05.001 [16] van Veldhuisen D J,Aass H,El Allaf D,et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study[J]. Eur J Heart Fail,2006,8(5):539-546. [17] Crijns H J,Tjeerdsma G,de Kam P J,et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure[J]. Eur Heart J,2000,21(15):1238-1245. [18] Morin D P,Bernard M L,Madias C,et al. The state of the art:atrial fibrillation epidemiology,prevention,and treatment[J]. Mayo Clin Proc,2016,91(12):1778-1810. doi: 10.1016/j.mayocp.2016.08.022 [19] 吴超,赵雪燕,袁晋青,等. NT-proANP、NT-proBNP和NT-proCNP对心力衰竭患者心源性事件预后预测价值的比较[J]. 中国分子心脏病学杂志,2021,21(3):3949-3952. [20] Yilmaz M B,Zorlu A,Bektaşoğlu G,et al. The product of eGFR and hemoglobin may help predict mortality in systolic heart failure patients without severe anemia and renal failure[J]. Turk Kardiyol Dern Ars,2012,40(1):9-15. doi: 10.5543/tkda.2012.01496 [21] 汪芸,王如兴. NT-proBNP联合肾小球滤过率对慢性心功能不全患者心衰程度的预测价值[J]. 江苏大学学报:医学版,2020,30(2):173-176. [22] 刘妮妮,张健. 射血分数降低和保留的心衰患者中房颤与NT-proBNP/BNP的关系[J]. 中国分子心脏病学杂志,2018,18(4):2559-2563. [23] 孙礼玲,周伟,刘子龙,等. NT-proBNP与阵发性房颤发生的相关性研究[J]. 临床医药文献杂志,2019,6(20):21-24. [24] Hijazi Z,Wallentin L,Siegbahn A,et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation:insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)[J]. J Am Coll Cardiol,2013,61(22):2274-2284. doi: 10.1016/j.jacc.2012.11.082 -
点击查看大图
图(4) / 表(2)
计量
- 文章访问数: 4919
- HTML全文浏览量: 2357
- PDF下载量: 28
- 被引次数: 0
